Cover Image

Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved

The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF)  > 40%. Here, we report th...

Full description

Saved in:
Bibliographic Details
Main Authors: Anker, Stefan (Author) , Butler, Javed (Author) , Usman, Muhammad Shariq (Author) , Filippatos, Gerasimos (Author) , Ferreira, João Pedro (Author) , Bocchi, Edimar (Author) , Böhm, Michael (Author) , Rocca, Hans Pieter Brunner-La (Author) , Choi, Dong-Ju (Author) , Chopra, Vijay (Author) , Chuquiure, Eduardo (Author) , Giannetti, Nadia (Author) , Gomez-Mesa, Juan Esteban (Author) , Janssens, Stefan (Author) , Januzzi, James L. (Author) , González-Juanatey, José R. (Author) , Merkely, Bela (Author) , Nicholls, Stephen J. (Author) , Perrone, Sergio V. (Author) , Piña, Ileana L. (Author) , Ponikowski, Piotr (Author) , Senni, Michele (Author) , Sim, David (Author) , Spinar, Jindrich (Author) , Squire, Iain (Author) , Taddei, Stefano (Author) , Tsutsui, Hiroyuki (Author) , Verma, Subodh (Author) , Vinereanu, Dragos (Author) , Zhang, Jian (Author) , Iwata, Tomoko (Author) , Schnee, Janet M. (Author) , Brückmann, Martina (Author) , Pocock, Stuart J. (Author) , Zannad, Faiez (Author)
Format: Article (Journal)
Language:English
Published: 05 December 2022
In: Nature medicine
Year: 2022, Volume: 28, Issue: 12, Pages: 2512-2520
ISSN:1546-170X
DOI:10.1038/s41591-022-02041-5
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41591-022-02041-5
Verlag, kostenfrei, Volltext: http://www.nature.com/articles/s41591-022-02041-5
Get full text
Author Notes:Stefan D. Anker, Javed Butler, Muhammad Shariq Usman, Gerasimos Filippatos, João Pedro Ferreira, Edimar Bocchi, Michael Böhm, Hans Pieter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure, Nadia Giannetti, Juan Esteban Gomez-Mesa, Stefan Janssens, James L. Januzzi, José R. González-Juanatey, Bela Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindrich Spinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragos Vinereanu, Jian Zhang, Tomoko Iwata, Janet M. Schnee, Martina Brueckmann, Stuart J. Pocock und Faiez Zannad
Description
Summary:The EMPEROR-Preserved trial showed that the sodium-glucose co-transporter 2 inhibitor empagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure (HHF) in heart failure patients with left ventricular ejection fraction (LVEF)  > 40%. Here, we report the results of a pre-specified analysis that separately evaluates these patients stratified by LVEF: preserved (≥ 50%) (n = 4,005; 66.9%) or mid-range (41-49%). In patients with LVEF  ≥ 50%, empagliflozin reduced the risk of cardiovascular death or HHF (the primary endpoint) by 17% versus placebo (hazard ratio (HR) 0.83; 95% confidence interval (CI): 0.71-0.98, P = 0.024). For the key secondary endpoint, the HR for total HHF was 0.83 (95%CI: 0.66-1.04, P = 0.11). For patients with an LVEF of 41-49%, the HR for empagliflozin versus placebo was 0.71 (95%CI: 0.57-0.88, P = 0.002) for the primary outcome (Pinteraction = 0.27), and 0.57 (95%CI: 0.42-0.79, P < 0.001) for total HHF (Pinteraction = 0.06). These results, together with those from the EMPEROR-Reduced trial in patients with LVEF < 40%, support the use of empagliflozin across the full spectrum of LVEF in heart failure.
Item Description:Gesehen am 27.08.2024
Physical Description:Online Resource
ISSN:1546-170X
DOI:10.1038/s41591-022-02041-5

Similar Items